Supernus Pharmaceuticals | SUPN - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Abbott USD 4.27B 669M 2026-09
ANI Pharmaceuticals USD 91.66M 18.01M 2026-06
Aurora Cannabis CAD 41.4M 781K 2026-03
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Canopy Growth CAD 31.17M 2.27M 2026-03
Cara Therapeutics USD 2.09M 96K 2026-03
Corcept Therapeutics USD 156.9M 28.85M 2026-06
Eisai JPY 114.83B 4.71B 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Novo Nordisk DKK 16.31B 3.09B 2026-06
Pacira USD 91.81M 7.93M 2026-06
Perrigo USD 3.28B 3.02B 2026-06
Pfizer USD 3.41B 496M 2026-06
Supernus Pharmaceuticals USD 133.64M 15.41M 2026-06
United Therapeutics USD 206.7M 50.1M 2026-06
Xeris Pharmaceuticals USD 53.14M 10.51M 2026-03